Company intelligence / Profile preview
Rhine Pharma
Heidelberg, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
RHN001 is in a Phase I/IIa clinical trial (RHINO Trial) evaluating safety and efficacy of both diagnostic (99mTc-RHN001) and therapeutic (188Re-RHN001) forms in advanced prostate cancer; results pending Q1 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeRadiopharmaceutical
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Telix PharmaceuticalsHeidelberg University HospitalNuMeRI (Nuclear Medicine Research Infrastructure, University of Pretoria)Oncidium FoundationOncobeta GmbH
Beyond the preview
Go deeper on Rhine Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rhine Pharma.